GlassScriptPhysician profile
Robin A Blume
NPI 1144539750
$18,368.74
in general payments reported to CMS, 2019-2025
53 companies · $4,371 in 2025
The $4,371 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,844 · 2022: $3,004 · 2023: $3,762 · 2024: $4,388 · 2025: $4,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,964.44 |
| Education | $556.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,011.78 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,674.98 | 2021-2025 | Ultomiris, Soliris |
| Pfizer INC. | $1,439.25 | 2023-2025 | |
| Ucb, INC. | $1,274.60 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,092.14 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $864.00 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $852.49 | 2021-2025 | |
| Sk Life Science, INC. | $718.34 | 2021-2025 | Xcopri |
| Argenx US, INC. | $708.61 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $514.85 | 2021-2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $456.47 | 2021-2022 | |
| Lilly USA, LLC | $455.39 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $448.49 | 2022 | |
| Emd Serono, INC. | $402.46 | 2022-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $385.10 | 2021-2025 | Nuplazid |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Blume listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.